Voluntary announcement cde approval of IND application for BA1203 (a masked anti-PD-1/IL-2 fusion protein)
Filed with HKEX · Stock code 6955 · · 2 pages · English
Boan Biotech博安生物 **Shandong Boan Biotechnology Co., Ltd.**山东博安生物技术股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 6955) VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) The board of directors (the “Board”) of Shandong Boan Biotechnology Co., Ltd. (the “Company”) announces tha
Shandong Boan Biotechnology Company., Limited on 6ix
Earlier from Shandong Boan Biotechnology
- Poll results of the annual general meeting held on 22 June 2026
- Voluntary announcement licensing of dulaglutide injection in the U.S.
Later from Shandong Boan Biotechnology
- Next Day Disclosure Return
- Interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Continuing connected transactions promotion cooperation agreement
- Voluntary announcement first subject enrolled in phase i clinical trial of BA1203 (a masked anti-PD-1/IL-2 fusion protein) in china
Follow Shandong Boan Biotechnology into a list and get an email when it puts out news.
Follow Shandong Boan Biotechnology